Navigation Links
Heparin-like compounds inhibit breast cancer metastasis to bone
Date:5/21/2012

Researchers from VTT Technical Research Centre of Finland have in collaboration with the University of Turku, Indiana University and two Finnish companies, Biotie Therapies Corp. and Pharmatest Services Ltd, discovered a novel mechanism regulating the development of breast cancer bone metastases and showed that heparin-like compounds can potentially be used to inhibit breast cancer metastasis to bone.

These findings were published on the Molecular Cancer Research journal website on 20th April 2012.

The researchers at VTT used RNA interference-based screening in breast cancer cells and found that an enzyme that modifies heparan sulfate glycosaminoglycans, HS6ST2, is an important regulator of breast cancer cellbone interactions. Heparin, which is commonly used as an anticoagulant, also inhibited this regulatory mechanism.

Experiments in a mouse model of breast cancer bone metastasis indicated that heparin-like compounds decreased bone destruction and tumor growth in bone. One of these heparin-like compounds, developed by Biotie Therapies, has a significantly reduced anticoagulant activity as compared to heparin, which improves its applicability as a potential cancer therapeutic agent.

Breast cancer that has metastasized to bone is currently an incurable disease, causing significant morbidity and mortality.


'/>"/>
Contact: Merja Perl, Principal Scientist
merja.perala@vtt.fi
358-207-222-825
VTT Technical Research Centre of Finland
Source:Eurekalert

Page: 1

Related biology news :

1. Duke team finds compounds that prevent nerve damage
2. Discovery of natural compounds that could slow blood vessel growth
3. New $11 million center to speed production of new compounds for drug discovery
4. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
5. Scripps research scientists identify compounds for stem-cell production from adult cells
6. Two new compounds show promise for eliminating breast cancer tumors
7. 2 new compounds show promise for eliminating breast cancer tumors
8. Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
9. Compounds could be new class of cancer drugs
10. MSU discoveries upend traditional thinking about how plants make certain compounds
11. Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
Breaking Biology News(10 mins):
(Date:3/24/2017)...   Sienna Biopharmaceuticals, Inc. , a privately held, ... Richard Peterson will join the company as ... who brings more than two decades of global financial ... retiring at the end of April but will continue ... Sienna from Novan, Inc., where he served as Chief ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... New York , March 23, 2017 ... blood plasma products and derivatives market is fragmented due to the presence ... players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete ... leader, these three companies, collectively, held more than 76% of this ... ...
Breaking Biology Technology: